Immunotherapy in Head and Neck Cancer—Where Are We Now and Where Are We Headed?
International Journal of Molecular Sciences · 19.01.2026 · 27 (2) · 987
DOI: 10.3390/ijms27020987 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.01.2026. Verfasst von Rafał Becht und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian University of Medicine, 71-252 Szczecin, Poland. Hauptthemen laut MEDLINE: Immunotherapy, Head and Neck Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pomeranian Medical University in Szczecin, Poland.
Abstract (Originalsprache)
Head and neck cancer (HNC) encompasses tumors located within the oral cavity, sinonasal cavity, pharynx, and larynx. It is the sixth most common cancer worldwide. Current treatment methods in HNC patients involve radical surgery, radical radiotherapy, and concomitant chemoradiotherapy, along with adjuvant and induction therapies. Accumulating trials examine the role of immunotherapy in patients with HNC. The results of the CheckMate-141 and KEYNOTE-048 trials demonstrated the benefits of using immunotherapy in patients with metastatic or recurrent HNC. Subsequently, numerous other immunotherapy-based protocols have been evaluated. Then, KEYNOTE-689 successfully implemented immunotherapy in patients with locally advanced disease. This review aims to comprehensively present the landscape of immunotherapy opportunities in patients with HNC. It summarizes completed key clinical trials that led to the approval of immunotherapy in HNC and presents currently performed trials with highly expected results. Furthermore, it discusses methods to improve immunotherapy outcomes in the cohort of HNC patients, describes the current role of immunotherapy in HNC, and presents future perspectives of this type of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian University of Medicine, 71-252 Szczecin, Poland.
- Maxillo-Facial Surgery Clinic, Pomeranian Medical University, 71-252 Szczecin, Poland.
- Department of Oncology, Dr. Peset University Hospital, Av.de Gaspar Aguilar 90, 46017 Valencia, Spain.
- Department of Otolaryngology, Pomeranian University of Medicine, 71-252 Szczecin, Poland.
ORCID-Profile: Rafał Becht, Kajetan Kiełbowski, Sebastian Ochenduszko, Inmaculada Maestu Maiques, Katarzyna Radomska
Förderung
- Pomeranian Medical University in Szczecin, Poland
Zitieren
APA
Becht, R., Kiełbowski, K., Żukowska, P., Kowalczyk, R., Ochenduszko, S., Maestu Maiques, I., & Radomska, K. (2026). Immunotherapy in Head and Neck Cancer—Where Are We Now and Where Are We Headed?. International Journal of Molecular Sciences, 27(2), 987. https://doi.org/10.3390/ijms27020987
Vancouver
Becht R, Kiełbowski K, Żukowska P, Kowalczyk R, Ochenduszko S, Maestu Maiques I, et al. Immunotherapy in Head and Neck Cancer—Where Are We Now and Where Are We Headed?. International Journal of Molecular Sciences. 2026;27(2):987. doi:10.3390/ijms27020987
BibTeX
@article{Becht2026,
author = {Becht, Rafał and Kiełbowski, Kajetan and Żukowska, Paulina and Kowalczyk, Robert and Ochenduszko, Sebastian and Maestu Maiques, Inmaculada and Radomska, Katarzyna},
title = {Immunotherapy in Head and Neck Cancer—Where Are We Now and Where Are We Headed?},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {987},
doi = {10.3390/ijms27020987}
}
EUVIMED